JTB and prostate carcinoma: Recent advances in proteomics, alongside genomic and transcriptomic studies, have provided robust evidence for JTB’s role in modulating EMT, metabolism reprogramming, immune evasion, and therapeutic resistance, particularly in breast and prostate cancers.